# Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

> **NCT07057310** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **Mayo Clinic** · enrollment: 30 (estimated)

## Conditions studied

- Obesity
- Menopause

## Interventions

- **DRUG:** semaglutide or tirzepatide
- **BEHAVIORAL:** Lifestyle modification intervention

## Key facts

- **NCT ID:** NCT07057310
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-05-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07057310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07057310, "Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07057310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*